{"id":18594,"date":"2023-01-23T12:28:47","date_gmt":"2023-01-23T12:28:47","guid":{"rendered":"https:\/\/clinlabint.com\/?p=18594"},"modified":"2023-01-23T12:30:46","modified_gmt":"2023-01-23T12:30:46","slug":"ubiquigent-collaborates-with-university-of-glasgow-on-translational-structural-biology-to-accelerate-drug-discovery-within-the-deubiquitylation-field","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/ubiquigent-collaborates-with-university-of-glasgow-on-translational-structural-biology-to-accelerate-drug-discovery-within-the-deubiquitylation-field\/","title":{"rendered":"Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field"},"content":{"rendered":"<div id='av_section_1'  class='avia-section main_color avia-section-default avia-no-border-styling  avia-bg-style-scroll  avia-builder-el-0  avia-builder-el-no-sibling   container_wrap fullsize' style=' '  ><div class='container' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-18594'><div class='entry-content-wrapper clearfix'>\n<div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding first  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><!--Begin ClixTrac.com Banner Code -->\r\n<a href=\"https:\/\/clixtrac.com\/goto\/?311442\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/clixtrac.com\/banner\/311442.jpg\" alt=\"Bio-Rad - Preparing for a Stress-free QC Audit\" title=\"Bio-Rad - Preparing for a Stress-free QC Audit\" border=\"0\" \/><\/a>\r\n<!--End ClixTrac.com Banner Code --><\/p>\n<\/div><\/section><\/div><div class=\"flex_column av_three_fifth  flex_column_div av-zero-column-padding   avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><header class=\"entry-content-header\"><h1 class=\"post-title entry-title\" itemprop=\"headline\">Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field<\/h1><span class=\"post-meta-infos\">\/ <span class=\"blog-categories minor-meta\">in <a href=\"https:\/\/clinlabint.com\/e-news\/\" rel=\"tag\">E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-6  el_after_av_textblock  el_before_av_textblock  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img decoding=\"async\" class=\"avia_image\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2023\/01\/image005-300x66.png\" alt=\"\" title=\"image005\" height=\"66\" width=\"300\" itemprop=\"thumbnailUrl\"><\/div><\/div><\/div><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3><em>Supporting Master\u2019s student in Prof Helen Walden\u2019s laboratory<\/em><\/h3>\n<ul>\n<li>\n<h3><em>Project aims to determine USP30 structure to inform the design and discovery of novel inhibitors<\/em><\/h3>\n<\/li>\n<\/ul>\n<p><!--more--><\/p>\n<p>Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master\u2019s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases. Overseen by structural biology experts Professor Helen Walden, UoG, and Dr Mehmet Gundogdu, Principal Scientist at Ubiquigent, the project aims to combine biochemistry,\u00a0<em>in vitro<\/em>\u00a0complex protein assembly and protein crystallography to interrogate the mechanism underlying USP30 inhibition by selected proprietary compounds. As well as promoting fundamental research on this strategic enzyme, the project will enable Ubiquigent\u2019s USP30 programme. The studentship is fully funded by Ubiquigent.<\/p>\n<p>USP30 regulates the clearance of damaged mitochondria in a process called mitophagy. Dysregulation of mitophagy is closely linked to the development of several diseases, with USP30 modulation offering a potential treatment; USP30 inhibition, for example, has been proposed as a therapeutic strategy for Parkinson\u2019s disease (PD). Although numerous USP30-targeting compounds are reported in scientific literature, only one has been approved to enter clinical evaluation so far, and the design and discovery of new compounds is hampered by a lack of a suitable USP30 crystal structure in the public domain. The project aims to overcome this barrier, bringing together the expertise of both groups to deliver a bespoke USP30 structural biology platform to identify novel inhibitors for treatment of a range of diseases including PD.<\/p>\n<\/div><\/section><br \/>\n<div   class='hr hr-default   avia-builder-el-8  el_after_av_textblock  el_before_av_image '><span class='hr-inner ' ><span class='hr-inner-style'><\/span><\/span><\/div><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-9  el_after_av_hr  el_before_av_textblock  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img decoding=\"async\" class=\"avia_image\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2023\/01\/Media_651736_smxx300-214x300.jpg\" alt=\"\" title=\"Media_651736_smxx300\" height=\"300\" width=\"214\" itemprop=\"thumbnailUrl\"><\/div><\/div><\/div><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p><strong>Professor Helen Walden, Professor of Structural Biology, Head of School (Molecular Biosciences), University of Glasgow, said:<\/strong>\u00a0<em>\u201cThere is huge potential to exploit USP30 as a therapeutic target across many indications, including cardiovascular, renal, and neurodegenerative diseases. My team has worked extensively on resolving the structures of both DUBs and E3 ligases, and I look forward to combining this experience with Ubiquigent\u2019s drug discovery expertise to support the Master\u2019s student and resolve the crystal structure of USP30 for the design of novel therapeutics.\u201d<\/em><\/p>\n<\/div><\/section><br \/>\n<div   class='hr hr-default   avia-builder-el-11  el_after_av_textblock  el_before_av_image '><span class='hr-inner ' ><span class='hr-inner-style'><\/span><\/span><\/div><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-12  el_after_av_hr  el_before_av_textblock  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img decoding=\"async\" class=\"avia_image\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2023\/01\/Mehmet-Gundogdu-2_300dpi-225x300.jpg\" alt=\"\" title=\"Mehmet Gundogdu 2_300dpi\" height=\"300\" width=\"225\" itemprop=\"thumbnailUrl\"><\/div><\/div><\/div><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p><b><span lang=\"EN-GB\">Dr Mehmet Gundogdu, Principal Scientist, Ubiquigent, commented:<\/span><\/b><span class=\"apple-converted-space\"><span lang=\"EN-GB\">\u00a0<\/span><\/span><em><span lang=\"EN-GB\">\u201c<i>Collaborating with Professor Walden on this project is an exciting opportunity to combine forces in an important therapeutic area. USP30 is a prominent target in the DUB drug discovery space, and this project has great potential to enable the structure-led design and development of novel USP30 modulators.\u201d<\/i><\/span><\/em><\/p>\n<\/div><\/section><br \/>\n<div   class='hr hr-default   avia-builder-el-14  el_after_av_textblock  el_before_av_image '><span class='hr-inner ' ><span class='hr-inner-style'><\/span><\/span><\/div><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-15  el_after_av_hr  el_before_av_textblock  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img decoding=\"async\" class=\"avia_image\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2023\/01\/Sheelagh-Frame-1_300dpi-225x300.jpg\" alt=\"\" title=\"Sheelagh Frame 1_300dpi\" height=\"300\" width=\"225\" itemprop=\"thumbnailUrl\"><\/div><\/div><\/div><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p><span class=\"apple-converted-space\"><span lang=\"EN-GB\"><b>Dr Sheelagh Frame, Chief Scientific Officer, Ubiquigent, added:<\/b> <\/span><\/span><i><span lang=\"EN-GB\">\u201cWe are delighted to support the Master\u2019s student, Niyati Gupta Kheskani,<span class=\"apple-converted-space\">\u00a0<\/span>in Professor Walden\u2019s laboratory. By determining the structure of USP30 in complex with proprietary inhibitor compounds, our joint objective is to further enable USP30-focused drug discovery and move one step closer to the clinic. This is a great opportunity to support the development of the next generation of scientists, as well as to strengthen our relationship with Professor Walden and her team.\u201d<\/span><\/i><\/p>\n<\/div><\/section><br \/>\n<div   class='hr hr-default   avia-builder-el-17  el_after_av_textblock  el_before_av_textblock '><span class='hr-inner ' ><span class='hr-inner-style'><\/span><\/span><\/div><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p><b><\/b><span lang=\"EN-GB\">To learn more about Ubiquigent\u2019s pipeline of novel DUB-targeting compounds, please visit<span class=\"apple-converted-space\">\u00a0<\/span><\/span><span lang=\"EN-GB\"><a href=\"https:\/\/www.ubiquigent.com\/pipeline\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.ubiquigent.com\/pipeline<\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p>\n<\/div><\/section><br \/>\n<div  class='av-social-sharing-box  avia-builder-el-19  el_after_av_textblock  avia-builder-el-last  av-social-sharing-box-minimal '><div class='av-share-box'><h5 class='av-share-link-description av-no-toc '>Share this<\/h5><ul class='av-share-box-list noLightbox'><li class='av-share-link av-social-link-facebook' ><a target=\"_blank\" aria-label=\"Share on Facebook\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/clinlabint.com\/ubiquigent-collaborates-with-university-of-glasgow-on-translational-structural-biology-to-accelerate-drug-discovery-within-the-deubiquitylation-field\/&#038;t=Ubiquigent%20collaborates%20with%20University%20of%20Glasgow%20on%20translational%20structural%20biology%20to%20accelerate%20drug%20discovery%20within%20the%20%28de%29ubiquitylation%20field\" aria-hidden=\"false\" data-av_icon=\"\ue8f3\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Facebook\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Facebook<\/span><\/a><\/li><li class='av-share-link av-social-link-twitter' ><a target=\"_blank\" aria-label=\"Share on Twitter\" href=\"https:\/\/twitter.com\/share?text=Ubiquigent%20collaborates%20with%20University%20of%20Glasgow%20on%20translational%20structural%20biology%20to%20accelerate%20drug%20discovery%20within%20the%20%28de%29ubiquitylation%20field&#038;url=https:\/\/clinlabint.com\/?p=18594\" aria-hidden=\"false\" data-av_icon=\"\ue8f1\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Twitter\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Twitter<\/span><\/a><\/li><li class='av-share-link av-social-link-whatsapp' ><a target=\"_blank\" aria-label=\"Share on WhatsApp\" href=\"https:\/\/api.whatsapp.com\/send?text=https:\/\/clinlabint.com\/ubiquigent-collaborates-with-university-of-glasgow-on-translational-structural-biology-to-accelerate-drug-discovery-within-the-deubiquitylation-field\/\" aria-hidden=\"false\" data-av_icon=\"\uf232\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on WhatsApp\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on WhatsApp<\/span><\/a><\/li><li class='av-share-link av-social-link-linkedin' ><a target=\"_blank\" aria-label=\"Share on LinkedIn\" href=\"https:\/\/linkedin.com\/shareArticle?mini=true&#038;title=Ubiquigent%20collaborates%20with%20University%20of%20Glasgow%20on%20translational%20structural%20biology%20to%20accelerate%20drug%20discovery%20within%20the%20%28de%29ubiquitylation%20field&#038;url=https:\/\/clinlabint.com\/ubiquigent-collaborates-with-university-of-glasgow-on-translational-structural-biology-to-accelerate-drug-discovery-within-the-deubiquitylation-field\/\" aria-hidden=\"false\" data-av_icon=\"\ue8fc\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on LinkedIn\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on LinkedIn<\/span><\/a><\/li><li class='av-share-link av-social-link-mail' ><a  aria-label=\"Share by Mail\" href='mailto:?subject=Ubiquigent%20collaborates%20with%20University%20of%20Glasgow%20on%20translational%20structural%20biology%20to%20accelerate%20drug%20discovery%20within%20the%20%28de%29ubiquitylation%20field&#038;body=https:\/\/clinlabint.com\/ubiquigent-collaborates-with-university-of-glasgow-on-translational-structural-biology-to-accelerate-drug-discovery-within-the-deubiquitylation-field\/' aria-hidden='false' data-av_icon='\ue805' data-av_iconfont='entypo-fontello' title='' data-avia-related-tooltip='Share by Mail'><span class='avia_hidden_link_text'>Share by Mail<\/span><\/a><\/li><\/ul><\/div><\/div><\/p><\/div><div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding   avia-builder-el-20  el_after_av_three_fifth  avia-builder-el-last  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Supporting Master\u2019s student in Prof Helen Walden\u2019s laboratory Project aims to determine USP30 structure to inform the design and discovery of novel inhibitors<\/p>\n","protected":false},"author":3,"featured_media":18600,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/18594"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=18594"}],"version-history":[{"count":3,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/18594\/revisions"}],"predecessor-version":[{"id":18603,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/18594\/revisions\/18603"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/18600"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=18594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=18594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=18594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}